A Phase 2 interventional study of Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC in Dry Eye Disease (DED) and Graft-Versus-Host Disease(GVHD), sponsored by Instituto de Investigación Biomédica de Salamanca. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Instituto de Investigación Biomédica de Salamanca · Phase 2, Interventional, and Treatment
This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host Disease (GVHD) and severe ocular involvement (DYD-dry eye disease). The primary objective is to evaluate the clinically and statistically significant improvement in the signs and symptoms associated with the disease.
Secondary objectives include:
Assessing the quality of life of patients treated with two doses of MSCs using the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire).
- Evaluating whether the cell dose impacts clinical improvement.
The trial includes 30 patients, divided into two groups of 15, and focuses on the assessment of dry eye disease, with the treatment based on MSC administration to improve clinical outcomes and quality of life for the patients.
1,367 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Instituto de Investigación Biomédica de Salamanca is the lead sponsor of 20 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6.25 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.
Drug: Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC
12.5 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.
Drug: Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC
Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.
Change in the integrity of the ocular surface
Significant improvement in the integrity of the ocular surface, measured by corneal staining with fluorescein. A clinically significant improvement is defined as an improvement in Superficial Punctate Keratitis (SPK) of at least one unit compared to baseline, according to the Oxford scale (range 0-5). If an epithelial defect is present, a reduction of at least ¾ of its initial size is required. The Oxford scale is a grading system used to assess ocular surface damage based on corneal and conjunctival staining with fluorescein or lissamine green dyes. It is commonly used to evaluate conditions like dry eye disease and superficial punctate keratitis (SPK). The scale ranges from 0 to 5, where 0 represents no staining (healthy eye) and 5 indicates severe staining and damage.
Time frame: six and twelve months from start of treatment
Change in tear production
Significant increase in tear production, evaluated using the Schirmer test with topical anesthesia, by at least 2 mm. The Schirmer test is a diagnostic test used to measure tear production and assess dry eye syndrome. It evaluates whether the eyes produce enough tears to keep them properly lubricated. Results are as follows: Normal: ≥10 mm of wetting after 5 minutes Mild to moderate dry eye: 5-10 mm Severe dry eye: ≤5 mm
Time frame: six and twelve months from start of treatment
Change in the degree of conjunctival hyperemia
Significant reduction in the degree of conjunctival hyperemia by at least one point (Efron scale, 0-4). The Efron Scale is a clinical grading scale used by eye care professionals to assess the severity of contact lens complications and ocular surface conditions. It provides a standardized way to evaluate changes in the cornea and conjunctiva. The scale ranges from 0 to 4, where: Grade 0 = Normal (No signs of damage) Grade 1 = Trace (Mild changes, barely noticeable) Grade 2 = Mild (Early signs of irritation or damage) Grade 3 = Moderate (Significant changes, requires attention) Grade 4 = Severe (Serious complications, may need treatment)
Time frame: six and twelve months from start of treatment
Change in the parameters related to the Meibomian glands
Significant improvement, by at least one point, in parameters related to the Meibomian glands. The Meibomian glands are specialized sebaceous glands located in the upper and lower eyelids, near the edges of the eyelids. They are crucial for maintaining the health of the ocular surface. When the Meibomian glands become blocked or inflamed, it leads to Meibomian Gland Dysfunction (MGD). This condition can result in Dry eye disease. It is measured using Efron scale. The scale ranges from 0 to 4, where: Grade 0 = Normal (No signs of damage) Grade 1 = Trace (Mild changes, barely noticeable) Grade 2 = Mild (Early signs of irritation or damage) Grade 3 = Moderate (Significant changes, requires attention) Grade 4 = Severe (Serious complications, may need treatment)
Time frame: six and twelve months from start of treatment
Change in any of the findings in the central cornea
Significant improvement in any of the findings in the central cornea, evaluated through in vivo confocal microscopy: 1. Improvement of at least one grade (three grades: corneal, mixed, conjunctival) in the epithelial phenotype. 2. Significant reduction in the density of dendritic cells in the corneal stroma. 3. Improvement in the characteristics of the sub-basal corneal nerve plexus (number of nerves, density, length, tortuosity, and nerve branching). All parameters are evaluated at the same time using the same samples, which will be analyzed by confocal microscopy.
Time frame: six and twelve months from start of treatment
Severity of eye disease measured by WFPRS (Wong-Baker Faces Pain Rating Scale)
The Wong-Baker Faces Pain Rating Scale (WFPRS) is a visual pain assessment tool that uses facial expressions to help individuals describe their pain intensity. The scale consists of six faces, ranging from a happy face (no pain) to a crying face (worst pain possible). Each face corresponds to a numerical value from 0 to 10: 0-No Pain: The patient experiences no discomfort or pain and feels completely normal. 2-Mild Pain: Slight discomfort is present but does not interfere with daily activities. No treatment necessary. 4-Moderate Pain: Noticeable pain or discomfort, which may cause mild difficulty in performing certain tasks but is still manageable. 6-Moderate to Severe Pain: Pain is more persistent and begins to interfere with concentration and daily functions. Medical attention may be needed. 8-Severe Pain: Significant pain that affects daily activities and requires immediate medical attention. 10-Worst Pain Possible: Extreme, unbearable pain that severily limits function.
Time frame: six and twelve months from start of treatment
Severity of eye disease measured by Numerical Rating Scale (NRS)
The Numerical Rating Scale (NRS) is a simple and widely used tool for assessing pain or symptom severity in patients. It typically asks individuals to rate their symptoms on a scale from 0 to 10, where: 0 = No symptoms (or no pain) 10 = Worst possible symptoms (or unbearable pain) In dry eye assessments, the NRS is often used to rate: Eye dryness (0 = no dryness, 10 = extreme dryness) Eye discomfort (0 = no discomfort, 10 = severe discomfort) It helps track symptom progression and evaluate treatment effectiveness over time.
Time frame: six and twelve months from start of treatment
Severity of eye disease measured by Modified Symptom Assessment in Dry Eye Questionnaire (mSIDEQ)
The Modified Symptom Assessment in Dry Eye Questionnaire (mSIDEQ) is a patient-reported questionnaire used to assess the severity and impact of dry eye disease (DED) symptoms. It is an improved version of the original Symptom Assessment in Dry Eye Questionnaire (SIDEQ) and is designed to be more concise and clinically relevant. Patients rate their symptoms on a numerical scale (e.g., 0-4 or 0-5, depending on the version). The total score reflects the overall burden of dry eye symptoms-higher scores indicate worse symptoms.
Time frame: six and twelve months from start of treatment
Severity of eye disease measured by Ocular Surface Disease Index (OSDI)
The Ocular Surface Disease Index (OSDI) is a questionnaire used to assess the severity of dry eye disease (DED) and other ocular surface disorders. It evaluates the frequency of dry eye symptoms, their impact on daily activities, and environmental triggers that might worsen the condition. The OSDI consists of 12 questions divided into three categories: * Ocular Symptoms (e.g., dry eye discomfort, grittiness, pain) * Visual Function (e.g., difficulty reading, driving, using a computer) * Environmental Triggers (e.g., sensitivity to wind or air conditioning) Each question is scored from 0 to 4 (0 = no problems, 4 = severe problems). the results are analised as follows: 0-12 → Normal 13-22 → Mild dry eye 23-32 → Moderate dry eye 33-100 → Severe dry eye
Time frame: six and twelve months from start of treatment
Severity of eye disease measured by CDES-Q (Contact Lens Dry Eye Symptom Questionnaire)
The Contact Lens Dry Eye Symptom Questionnaire (CDES-Q) is a patient-reported questionnaire designed to assess dry eye symptoms in contact lens wearers. It helps evaluate symptom severity, frequency, and impact on daily activities to better understand and manage contact lens-related dry eye (CLDE). Patients typically rate the frequency and severity of symptoms like: * Dryness or discomfort while wearing lenses * Burning or stinging sensations * Foreign body sensation (feeling like something is in the eye) * Blurred vision or fluctuating clarity * Lens awareness or intolerance over time Higher scores indicate more severe dry eye symptoms related to contact lens wear.
Time frame: six and twelve months from start of treatment
Rate of adverse events related to the administration of subconjunctival ASC injection.
The investigator will record in the eCRF and communicate to the sponsor or to the person assuming the tasks delegated by the sponsor, the adverse events (AEs) that are considered of special interest occurring during the study as soon as possible, and no later than 15 days after becoming aware of them. The AEs considered of special interest are: Immunogenicity reactions and their consequences. Adverse events possibly due to unexpected reactions such as hypersensitivity, immunological, toxic reactions, and migration of cells from the application site. Adverse events related to product failure that may be associated with the production process or with the quality of the investigational product.
Time frame: Through study completion, an average of 1 year
Analysis of ocular marker expression in the administered ASCs
The expression of the markers cytokeratin K3 and K12, specific to differentiated corneal epithelium, and the markers K15, nuclear transcription factor p63alpha (p63alpha), and ABCG2 transporter protein, specific to limbal corneal epithelium markers, will be analyzed using an immunodetection technique (immunofluorescence). It will also be analyzed how the freezing process of ASCs may affect these markers and, if possible, establish a correlation between the expression of these markers in the applied cells and the clinical outcomes.
Time frame: When vials are thawed before treating the first patients with 6.25 mill and 12.5 mill ASC, 1 year afterwards and two years afterwards or altertatively, when vials are thawed to treat the last patient with 6.25 and 12.5 mill ASC.
Analysis of the presence and concentration of inflammation-related molecules in tear and serum samples
The presence and concentration of 48 inflammation-related molecules in tear and serum samples will be studied using the "Human Cytokine/Chemokine/Growth Factor Panel Cat. No. HCYTA-60KPXBK48" kit and XMAP™ technology (Luminex Corporation, Austin, TX, USA). All molecules are analyzed simultaneously, and their concentrations are measured in the same units, allowing for a combined analysis.
Time frame: Visit 2 (day 14 ± 7 after screening), 6 months, 12 months and when applicable, at premature withdrawal.
Search for new biomarkers that can be used to objectively evaluate the progression of patients affected by EICRc with ocular involvement.
The search for biomarkers aims at the development of predictive models that help improve the diagnosis of EICRc and the prognosis of these patients based on the expression of certain genes.
Time frame: Visit 2 (day 14 ± 7 after screening), 6 months, 12 months and when applicable, at premature withdrawal.
No study locations are listed for this record.
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest (non-commercial interest) in advanced therapy in eye pathology, as dry eye. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Access criteria: Any qualified researcher with academic interest migh ask acces to IPD after previous approval of the request by the project manager.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2029, 25 months later.
Of 91 phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 12. This study's planned 25 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Oct 2026 → Dec 2026, primary completion Jun 2027 → Jan 2029 and completion Jun 2028 → Jun 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Biomédica de Salamanca